Janice Dutcher

4.8k total citations · 1 hit paper
13 papers, 3.6k citations indexed

About

Janice Dutcher is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Janice Dutcher has authored 13 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Janice Dutcher's work include Renal cell carcinoma treatment (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers) and Cancer Treatment and Pharmacology (3 papers). Janice Dutcher is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers) and Cancer Treatment and Pharmacology (3 papers). Janice Dutcher collaborates with scholars based in United States, Canada and Poland. Janice Dutcher's co-authors include Robert A. Figlin, Timothy E. O’Toole, Jeffrey A. Sosman, Stephanie Lustgarten, Vladimir Lesovoy, Robert J. Motzer, Elżbieta Starosławska, Piotr Tomczak, David McDermott and Ingo G.H. Schmidt‐Wolf and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Janice Dutcher

13 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 2.8k citations Gary R. Hudes, Michael A. Carducci et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Janice Dutcher United States	9	2.6k	2.4k	1.4k	1.1k	276	13	3.6k
David McDermott United States	3	2.3k 0.9×	2.2k 0.9×	1.3k 0.9×	807 0.8×	301 1.1×	3	3.2k
Zoran Kovačević Serbia	7	2.1k 0.8×	2.0k 0.8×	1.1k 0.8×	723 0.7×	246 0.9×	31	3.0k
Erhan Gökmen Türkiye	12	2.2k 0.9×	2.1k 0.9×	1.3k 0.9×	1.0k 1.0×	264 1.0×	56	3.4k
Norbert Hollaender Switzerland	15	2.5k 1.0×	2.4k 1.0×	1.3k 0.9×	1.0k 1.0×	295 1.1×	29	4.0k
Debasish Roychowdhury United States	12	2.1k 0.8×	1.5k 0.6×	876 0.6×	1.1k 1.0×	284 1.0×	19	3.1k
E Solska United States	4	3.9k 1.5×	3.3k 1.4×	2.1k 1.5×	1.9k 1.8×	444 1.6×	7	5.5k
Gladys Urbanowitz United States	8	2.2k 0.9×	1.9k 0.8×	996 0.7×	2.0k 1.9×	575 2.1×	12	4.2k
N. Moore Switzerland	16	2.6k 1.0×	1.7k 0.7×	1.2k 0.9×	2.0k 1.8×	266 1.0×	27	4.0k
Minghua Shan United States	17	4.0k 1.6×	3.3k 1.4×	2.1k 1.5×	2.0k 1.9×	460 1.7×	39	6.0k
Oleg Gladkov Russia	18	2.3k 0.9×	1.8k 0.8×	1.1k 0.8×	1.8k 1.7×	285 1.0×	65	3.7k

Countries citing papers authored by Janice Dutcher

Since Specialization

Citations

This map shows the geographic impact of Janice Dutcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice Dutcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice Dutcher more than expected).

Fields of papers citing papers by Janice Dutcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice Dutcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice Dutcher. The network helps show where Janice Dutcher may publish in the future.

Co-authorship network of co-authors of Janice Dutcher

This figure shows the co-authorship network connecting the top 25 collaborators of Janice Dutcher. A scholar is included among the top collaborators of Janice Dutcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janice Dutcher. Janice Dutcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Haas, Naomi B., Judith Manola, Bonnie Ky, et al.. (2015). Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clinical Cancer Research. 21(18). 4048–4054. 46 indexed citations

Flaherty, Keith T., Judith Manola, Michael Pins, et al.. (2015). BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804). Journal of Clinical Oncology. 33(21). 2384–2391. 75 indexed citations

Gordon, Michael S., Michael A. Hussey, Raymond B. Nagle, et al.. (2009). Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317. Journal of Clinical Oncology. 27(34). 5788–5793. 72 indexed citations

Hudes, Gary R., Michael A. Carducci, Piotr Tomczak, et al.. (2007). Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 356(22). 2271–2281. 2817 indexed citations breakdown →

Bukowski, Ronald M., Fairooz F. Kabbinavar, Robert A. Figlin, et al.. (2007). Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer. Journal of Clinical Oncology. 25(29). 4536–4541. 231 indexed citations

Dutcher, Janice, et al.. (2005). A Review of Evidence-Based Treatment of Stage IIB to Stage IV Melanoma. Cancer Investigation. 23(4). 323–337. 1 indexed citations

Alexandrescu, Doru T, et al.. (2004). Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma. Leukemia & lymphoma. 45(11). 2321–2325. 51 indexed citations

Rowinsky, Eric K., Garry Schwartz, Jared Gollob, et al.. (2004). Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer. Journal of Clinical Oncology. 22(15). 3003–3015. 243 indexed citations

Oiseth, Stanley J., Joachim Z. Fuks, Lydia Koulova, et al.. (2003). Metastatic Choriocarcinoma in a Middle-Aged Man Presenting as a Right Thigh Mass with Venous Thrombosis: A Case Report. Medical Oncology. 20(2). 189–194. 3 indexed citations

10.

Frishman, William H., et al.. (2001). Cardiovascular Considerations With Anthracycline Use in Patients With Cancer. PubMed. 3(3). 157–168. 8 indexed citations

11.

Frishman, William H., et al.. (1997). Cardiovascular toxicity with cancer chemotherapy. Current Problems in Cancer. 21(6). 301–360. 50 indexed citations

12.

Frishman, William H., et al.. (1996). Cardiovascular toxicity with cancer chemotherapy. Current Problems in Cardiology. 21(4). 227–286. 30 indexed citations

13.

Margolin, Kim, James H. Doroshow, Steven A. Akman, et al.. (1993). Phase I Trial of Interleukin-2 plus Doxorubicin. Journal of Immunotherapy. 14(1). 70–76. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact